OTC · Drug Manufacturers - Specialty & Generic

Eisai Co., Ltd. (ESALF) Stock

$26.18 +0.00% OTC: ESALF Healthcare

Eisai Co., Ltd., a pharmaceutical company headquartered in Tokyo, Japan, develops and markets a wide array of medicinal products. Its offerings for neurological conditions include Aricept, prescribed for Alzheimer's disease and dementia with Lewy bodies; Methycobal, used to treat peripheral neuropathy; Fycompa, an antiepileptic drug that serves as an adjunctive therapy for specific partial-onset and primary generalized tonic-clonic seizures; Lyrica, for various pain management needs; and Dayvigo, an anti-insomnia medication for adults.

Valuation

MetricValue
Price$26.18
Market Cap$7.39B
P/E Ratio33.27
P/B Ratio1.43
P/S Ratio1.56
EPS (TTM)$0.79
52-Week High$35.83
52-Week Low$23.88
Dividend Yield3.74%

Financials & Margins

MetricValue
ROE4.44%
ROA2.66%
ROCE3.63%
Gross Margin76.83%
Operating Margin4.87%
Net Margin4.67%
Debt/Equity0.21
Current Ratio2.24

Annual Financials (USD)

Metric20212022202320242025
Revenue$756.2B$744.4B$741.8B$789.4B$830.6B
Operating Profit$53.8B$40.0B$53.4B$54.4B$40.5B
Net Profit$48.0B$55.4B$42.4B$46.4B$38.8B
EPS$167.25$193.30$147.86$163.76$137.41
Op Margin7.1%5.4%7.2%6.9%4.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.24T$1.26T$1.39T$1.39T$1.46T
Total Liabilities$467.8B$440.8B$494.8B$520.6B$527.3B
Cash$309.6B$267.4B$304.7B$265.6B$247.0B
Borrowings$143.0B$126.1B$159.4B$187.5B$187.3B

Latest News

Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Disease CNW Group · Jul 16, 2026 Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers' Investor's Business Daily · Jul 14, 2026 LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment GlobeNewswire · Jul 14, 2026 How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval Simply Wall St. · Jul 14, 2026 FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease PR Newswire · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$117.6B$-1.8B$56.0B$30.1B$61.7B
Investing Cash Flow$-69.3B$-57.3B$-50.1B$-33.1B$-57.5B
Financing Cash Flow$-8.0B$-9.8B$-10.1B$-40.5B$-11.6B
Net Cash Flow$60.9B$-42.3B$37.3B$-39.1B$-35.9B
Free Cash Flow$77.1B$-36.3B$31.2B$7.1B$46.3B

Valuation & Return Ratios

MetricValue
PEG Ratio-2.01
EV / EBITDA12.77
FCF Yield3.58%
Quick Ratio1.48
Interest Coverage7.54
Return 1Y5.70%
Return 3Y-56.39%
Return 5Y—

Ownership

Insiders Held2.18%
Institutions Held56.14%
Institutions Float Held57.39%
Institutional HolderSharesReport Date
Pacer Advisors, Inc.2,3522026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIOVFSwedish Orphan Biovitrum AB (publ) $49.03 +0.00% 173.58 $16.96B 0.00%
GIFLFGrifols, S.A. $10.25 +0.00% 15.97 $6.98B 0.88%
GIFOFGrifols, S.A. $8.85 +0.00% 15.97 $8.70B 1.24%
KYKOFKyowa Kirin Co., Ltd. $14.43 +0.00% 18.86 $7.55B 3.12%
NOBDFNorth Bud Farms Inc. $0.00 — 0.00 $634 0.00%

About Eisai Co., Ltd.

Eisai Co., Ltd., a pharmaceutical company headquartered in Tokyo, Japan, develops and markets a wide array of medicinal products. Its offerings for neurological conditions include Aricept, prescribed for Alzheimer's disease and dementia with Lewy bodies; Methycobal, used to treat peripheral neuropathy; Fycompa, an antiepileptic drug that serves as an adjunctive therapy for specific partial-onset and primary generalized tonic-clonic seizures; Lyrica, for various pain management needs; and Dayvigo, an anti-insomnia medication for adults. In the oncology field, Eisai provides Lenvima, a molecularly targeted anticancer agent for thyroid cancer, renal cell carcinoma (when used in combination with everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. The company's portfolio also features Pariet, a proton-pump inhibitor effective in treating gastric and duodenal ulcers, reflux esophagitis, and for the eradication of Helicobacter pylori infections. Additionally, Eisai markets Humira, a fully human anti-TNF-alpha monoclonal antibody employed in managing autoimmune diseases such as rheumatoid arthritis. Beyond prescription medicines, Eisai provides consumer health products like Chocola BB Plus, a vitamin B2 preparation addressing rough skin and stomatitis, alongside various third-class over-the-counter (OTC) drugs, designated quasi-drugs, and functional foods. The company was established in 1941, initially operating as Nihon Eisai Co., Ltd., before adopting its current name, Eisai Co., Ltd., in 1955.

Eisai Co., Ltd. is headquartered in JP.

Eisai Co., Ltd. (ESALF) stock trades at $26.18 with a market capitalization of $7.39B. The stock is valued at a price-to-earnings (P/E) ratio of 33.27, price-to-book of 1.43, price-to-sales of 1.56. Over the past 52 weeks the stock has ranged between $23.88 and $35.83, and currently trades 26.9% below its 52-week high. It pays a dividend yielding 3.74%.

On profitability, Eisai Co., Ltd. generates a return on equity (ROE) of 4.44%, return on capital employed of 3.63%, an operating margin of 4.87%, a net profit margin of 4.67%.

Official website: www.eisai.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides